Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 4.17
OCRX's Cash to Debt is ranked lower than
67% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. OCRX: 4.17 )
Ranked among companies with meaningful Cash to Debt only.
OCRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.68  Med: 5.06 Max: No Debt
Current: 4.17
Equity to Asset 0.65
OCRX's Equity to Asset is ranked lower than
56% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. OCRX: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
OCRX' s Equity to Asset Range Over the Past 10 Years
Min: -1.09  Med: 0.68 Max: 0.96
Current: 0.65
-1.09
0.96
F-Score: 2
Z-Score: -3.58
M-Score: -0.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -19955.56
OCRX's Operating margin (%) is ranked lower than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. OCRX: -19955.56 )
Ranked among companies with meaningful Operating margin (%) only.
OCRX' s Operating margin (%) Range Over the Past 10 Years
Min: -19801.5  Med: -3770.24 Max: -63.42
Current: -19955.56
-19801.5
-63.42
Net-margin (%) -20284.44
OCRX's Net-margin (%) is ranked lower than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. OCRX: -20284.44 )
Ranked among companies with meaningful Net-margin (%) only.
OCRX' s Net-margin (%) Range Over the Past 10 Years
Min: -20604.71  Med: -3822.91 Max: -77.84
Current: -20284.44
-20604.71
-77.84
ROE (%) -76.68
OCRX's ROE (%) is ranked lower than
76% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. OCRX: -76.68 )
Ranked among companies with meaningful ROE (%) only.
OCRX' s ROE (%) Range Over the Past 10 Years
Min: -236.08  Med: -65.05 Max: -49.17
Current: -76.68
-236.08
-49.17
ROA (%) -60.73
OCRX's ROA (%) is ranked lower than
77% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. OCRX: -60.73 )
Ranked among companies with meaningful ROA (%) only.
OCRX' s ROA (%) Range Over the Past 10 Years
Min: -230.64  Med: -65.79 Max: -35.31
Current: -60.73
-230.64
-35.31
ROC (Joel Greenblatt) (%) -35073.11
OCRX's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. OCRX: -35073.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46351.52  Med: -3742.56 Max: -526.49
Current: -35073.11
-46351.52
-526.49
Revenue Growth (3Y)(%) -87.90
OCRX's Revenue Growth (3Y)(%) is ranked lower than
92% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. OCRX: -87.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -88.90 Max: -85.9
Current: -87.9
EBITDA Growth (3Y)(%) -47.30
OCRX's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. OCRX: -47.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -53.10 Max: -26.4
Current: -47.3
EPS Growth (3Y)(%) -50.20
OCRX's EPS Growth (3Y)(%) is ranked lower than
91% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. OCRX: -50.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -54.20 Max: -31.7
Current: -50.2
» OCRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

OCRX Guru Trades in Q2 2015

Jim Simons 35,200 sh (New)
» More
Q3 2015

OCRX Guru Trades in Q3 2015

Jim Simons 58,200 sh (+65.34%)
» More
Q4 2015

OCRX Guru Trades in Q4 2015

Jim Simons 105,100 sh (+80.58%)
» More
Q1 2016

OCRX Guru Trades in Q1 2016

Jim Simons 146,400 sh (+39.30%)
» More
» Details

Insider Trades

Latest Guru Trades with OCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XKRX:217950, TSE:4584, TSX:AUP, AMEX:ATNM, AMEX:PLX, ASX:ACR » details
Traded in other countries:6TY1.Germany,
Ocera Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of proprietary compounds to treat acute and chronic orphan liver disease.

Ocera Therapeutics Inc was incorporated in Delaware on December 20, 2004. The Company is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of OCR-002 for the treatment of hepatic encephalopathy or HE. OCR-002 is a novel molecule, ornithine phenylacetate, which functions as an ammonia scavenger. In pre-clinical studies, OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia, brain ammonia and intracranial pressure in a second animal model of acute liver failure. OCR-002 has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant HE in patients with acute liver failure and acute-on-chronic liver disease. OCR-002 has also been granted orphan drug designation in the European Union for the treatment of acute liver failure. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat HE. The Company is subject to federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Ratios

vs
industry
vs
history
P/B 2.02
OCRX's P/B is ranked higher than
72% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. OCRX: 2.02 )
Ranked among companies with meaningful P/B only.
OCRX' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 2.40 Max: 10.5
Current: 2.02
0.98
10.5
P/S 361.45
OCRX's P/S is ranked lower than
91% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. OCRX: 361.45 )
Ranked among companies with meaningful P/S only.
OCRX' s P/S Range Over the Past 10 Years
Min: 0.1  Med: 210.32 Max: 3600
Current: 361.45
0.1
3600
Current Ratio 8.07
OCRX's Current Ratio is ranked higher than
70% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. OCRX: 8.07 )
Ranked among companies with meaningful Current Ratio only.
OCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 7.25 Max: 21.99
Current: 8.07
0.62
21.99
Quick Ratio 8.07
OCRX's Quick Ratio is ranked higher than
71% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. OCRX: 8.07 )
Ranked among companies with meaningful Quick Ratio only.
OCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 7.25 Max: 21.99
Current: 8.07
0.62
21.99
Days Sales Outstanding 251.44
OCRX's Days Sales Outstanding is ranked lower than
92% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. OCRX: 251.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.55  Med: 161.92 Max: 399.35
Current: 251.44
23.55
399.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.13
OCRX's Price/Net Cash is ranked higher than
83% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. OCRX: 2.13 )
Ranked among companies with meaningful Price/Net Cash only.
OCRX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.54  Med: 2.84 Max: 10.42
Current: 2.13
1.54
10.42
Price/Net Current Asset Value 2.07
OCRX's Price/Net Current Asset Value is ranked higher than
83% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. OCRX: 2.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OCRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.35  Med: 2.77 Max: 8.97
Current: 2.07
1.35
8.97
Price/Tangible Book 2.06
OCRX's Price/Tangible Book is ranked higher than
75% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. OCRX: 2.06 )
Ranked among companies with meaningful Price/Tangible Book only.
OCRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.24  Med: 2.55 Max: 7.99
Current: 2.06
1.24
7.99
Price/Median PS Value 1.72
OCRX's Price/Median PS Value is ranked lower than
80% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. OCRX: 1.72 )
Ranked among companies with meaningful Price/Median PS Value only.
OCRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.43 Max: 13.44
Current: 1.72
0.01
13.44
Earnings Yield (Greenblatt) (%) -112.97
OCRX's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. OCRX: -112.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -113  Med: 105.40 Max: 167
Current: -112.97
-113
167

More Statistics

Revenue (TTM) (Mil) $0.14
EPS (TTM) $ -1.34
Beta2.61
Short Percentage of Float1.49%
52-Week Range $2.00 - 4.80
Shares Outstanding (Mil)21.31

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 0 0
EPS ($) -1.44 -1.85
EPS without NRI ($) -1.44 -1.85
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for OCRX

Headlines

Articles On GuruFocus.com
Three Insider Buys at 52-Week Lows Jul 22 2014 
Weekly CEO Buys Highlight: OPK, QTET, MIC, FAST, OCRX Jul 21 2014 
Top 3 Insider Buys of the Week Jul 19 2013 

More From Other Websites
Biotech-Focused VHCP Management’s Bullish Moves and New Picks May 24 2016
OCERA THERAPEUTICS, INC. Financials May 10 2016
OCERA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 03 2016
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 29 2016
Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress Apr 29 2016
Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia... Apr 15 2016
Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia... Apr 15 2016
Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia... Apr 11 2016
ETF’s with exposure to Ocera Therapeutics, Inc. : April 8, 2016 Apr 07 2016
Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: 2015 By the Numbers Apr 06 2016
Ocera to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Ocera to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
LifeSci Capital Initiates Coverage of Ocera Therapeutics Mar 24 2016
OCERA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 11 2016
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 03 2016
Ocera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides... Mar 03 2016
Ocera to Present at the Cowen and Company 36th Annual Health Care Conference Feb 29 2016
OCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jan 08 2016
Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in... Jan 08 2016
Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer Jan 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)